The Charles Bronfman Institute for Personalized Medicine

Why BioMe?

BioMe is the only biobank in New York City that performs non-selective enrollment, leading to a cohort unmatched in ethnic, socio-economic, and medical diversity and ready to be tapped for the broadest variety of biomedical and genetic research possible. Practically a microcosm of New York itself, BioMe represents the neighborhoods throughout the Mount Sinai Health System, its ethnic diversity manifesting itself in scores of mini BioMe cohorts representing nearly every nation in the world.

A Biobank as Unique as Its Participants

Our biobank is as unique as its many participants and includes these features:

  • Electronic Medical Records– enabled linkage for designing studies involving longitudinal follow-up
  • Highly interactive participant model
  • Enterprise data warehouse
  • Strong IT Department support
  • High-performance computing (Minerva)
  • Big data capabilities
  • Data and analysis for discovery projects under the sponsorship of global genomics consortia/networks
  • Supports research projects by local Mount Sinai faculty and external investigators
  • More than 260 manuscripts published by faculty at The Institute for Personalized Medicine since 2012 

Federally Verified, High-Quality Standards

The BioMe biorepository is the only biorepository in New York accredited by the College of American Pathologists (CAP) and is one of only two biorepositories in the tri-state area to achieve accreditation. BioMe is among the less than 1 percent of domestic biorepositories that are accredited by CAP. The organization’s Biorepository Accreditation Program (BAP) is recognized by the U.S. federal government. While there is no federal mandate for biorepository accreditation, patient donors and collaborators can recognize and trust our validated, high-quality standards and practices.